Q2 EPS Forecast for Tenax Therapeutics Lowered by Analyst

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Investment analysts at Roth Capital reduced their Q2 2025 earnings estimates for Tenax Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will earn ($0.19) per share for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.96) EPS.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20.

A number of other brokerages have also weighed in on TENX. Guggenheim reiterated a “buy” rating and set a $15.00 target price on shares of Tenax Therapeutics in a research report on Thursday, May 15th. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a report on Monday, March 10th. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. Finally, StockNews.com initiated coverage on Tenax Therapeutics in a report on Friday, May 16th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock opened at $6.00 on Monday. The firm has a market cap of $24.89 million, a PE ratio of -2.42 and a beta of 1.92. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89. The stock has a fifty day moving average price of $5.85 and a 200-day moving average price of $5.93.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TENX. Janus Henderson Group PLC purchased a new position in shares of Tenax Therapeutics during the fourth quarter worth about $1,026,000. ADAR1 Capital Management LLC increased its stake in shares of Tenax Therapeutics by 98.1% in the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock worth $450,000 after buying an additional 34,048 shares during the period. Millennium Management LLC purchased a new position in shares of Tenax Therapeutics in the fourth quarter worth $166,000. Geode Capital Management LLC raised its holdings in shares of Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,964 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of Tenax Therapeutics during the fourth quarter valued at approximately $84,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.